0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Obituary |

In Memoriam: John F. Kurtzke, MD (1926-2015) A Founding Father of Neuroepidemiology and Pioneer of Modern Clinical Trial Design FREE

Elliot M. Frohman, MD, PhD1,2; Olaf Stüve, MD, PhD2; Teresa C. Frohman, PA-C2,3,4; Robert Lisak, MD5,6
[+] Author Affiliations
1Department of Ophthalmology, University of Texas Southwestern School of Medicine, Dallas
2Department of Neurology and Neurotherapeutics, University of Texas Southwestern School of Medicine, Dallas
3Department of Bioengineering and Computer Science, University of Texas, Dallas
4Department of Behavioral and Brain Sciences, University of Texas, Dallas
5Department of Neurology, Wayne State School of Medicine, Detroit, Michigan
6Department of Immunology and Microbiology, Wayne State School of Medicine, Detroit, Michigan
JAMA Neurol. 2016;73(4):482-483. doi:10.1001/jamaneurol.2016.0030.
Text Size: A A A
Published online

On December 1, 2015, we lost one of the most influential contributors to the field of medical epidemiology, and in particular the man who is credited for performing the most systematic exploration of the geographic distribution patterns for the most common disabling neurologic disorder of young people, multiple sclerosis (MS). John F. Kurtzke, MD, graduated from the Cornell Medical College in 1952, and by 1956 he had ascended to the position of chief of neurology for the Veterans Administration in Coatesville, Pennsylvania. He would later serve as professor of neurology at Georgetown University from 1963 to 1995, during which time he conducted some of the most seminal investigations that collectively helped to establish the field of neuroepidemiology.

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

John F. Kurtzke, MD

The role of one or more environmental factors, including infections, as a critical factor in the pathogenesis of MS is now widely recognized. It was Kurtzke’s pioneering work that brought forth some of the most persuasive evidence to date supporting a putative role for an infectious agent as a contributing factor in MS.

When the presence of the disorder was nearly unheard of on the remote Faeroe Islands and in Iceland, the recording of many cases of MS following the occupation of these territories by the British troops during World War II fostered Kurtzke’s exploration into the infectious etiologic hypothesis as a contributing factor in the development of MS.18

The contemporary framework for the pathobiological underpinnings of MS is now most consistent with that of an epigenetic disorder predicated on genetic, environmental, nutritional, and behavioral factors, in conjunction with a factor acting as a trigger or “ignition switch.” Kurtzke’s observations and interpretive conclusions resonate with contemporary thinking, particularly given his hypothesis that a modifying etiological factor for developing MS appeared to be influenced by the location, with respect to equatorial latitude, of early life development, with mounting evidence that corroborates the postulated role of vitamin D as a critical mitigating influence potentially linked to its relationship to immune regulatory networks and the derivative achievement of self-tolerance.

Kurtzke’s second major accomplishment was the development of the disability status scale score, which catapulted the clinical assessment within clinical trials from the reporting of the assessor’s subjective impressions to the establishment of an objective, reproducible, and stereotyped gold-standard neurological examination and status ascertainment.9,10 This formidable contribution to the field of medical therapeutics resulted in the transformation of clinical trial design for MS in particular and set forth objective standards for the characterization of clinical outcomes to be emulated for disabling neurologic disorders in general.

Originally proposed in 1955 and 1961, Kurtzke formulated an ordinal scale for the application in MS drug trials (initially for the assessment of isoniazid as a treatment for MS) as a means to objectify the effects of putative therapies on the clinical disposition of neurologic disability in MS.9

Initially conceived as a scale from 0 (no evidence of signs, symptoms, or report of disabling changes in neurologic functioning or status) to 10 (death due to MS or its complications), the scale was later transformed into 0.5-point steps (the Expanded Disability Status Scale score) to account for the functional integrity of each of the functional system scales such as abnormalities affiliated with each of the components of the neurological examination: vision, brainstem functions, pyramidal functions (strength, reflexes, tone), cerebellar functions, sensory functions, bowel-bladder-sexual functions, cerebral functions (depression, euphoria, reduced mentation), and ambulation.10

The scale is an ordinal scale, heavily weighted on the impact and deterioration in walking, other motor functions, and, to a degree, sensory and visual functions. Notwithstanding the ordinal nature of the scale, the heavy bias on ambulation, and the subordination of critical functional deficits such as cognition and fatigue that contribute to disability and severity and are often major factors in the loss of gainful employment for patients with MS, the scale has remained the iconic gold standard for the assessment of disability, against which every attempted new iteration and new scale is compared.

For his monumental contributions to the field, Kurtzke was awarded the 1997 John Dystel Prize for MS Research by the American Academy of Neurology and the National Multiple Sclerosis Society, and in 1999 he received the highly coveted Charcot Award. In his honor, the Consortium of Multiple Sclerosis Centers, the Foundation of the CMSC, the American Academy of Neurology, and the American Brain Foundation created the John F. Kurtzke Clinician-Scientist Development Award, a 3-year training grant to promote and foster the next generation of MS physician investigators.

John F. Kurtzke was a gentleman of the “old school,” a devoted family man, and an active member of the MS community until his death. He could always be seen at the American Academy of Neurology meetings and at MS specialty meetings at platform and poster sessions, interacting with colleagues of long standing and in particular with junior colleagues including residents, fellows, and students. The use of the term giant has been used perhaps too readily but not here. Kurtzke was indeed a giant and a legend in the field of neurology.

Our sympathies go out to his wife Peggy and his family.

ARTICLE INFORMATION

Corresponding Author: Elliot M. Frohman, MD, PhD, Department of Neurology and Neurotherapeutics, University of Texas Southwestern School of Medicine, 5323 Harry Hines Blvd, Dallas, TX 75390 (elliot.frohman@utsouthwestern.edu).

Conflict of Interest Disclosures: None reported.

REFERENCES

Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroes, 1: clinical and epidemiologic features. Trans Am Neurol Assoc. 1978;103:201-205.
PubMed
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, I: clinical and epidemiological features. Ann Neurol. 1979;5(1):6-21.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, II: clinical update, transmission, and the nature of MS. Neurology. 1986;36(3):307-328.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, III: an alternative assessment of the three epidemics. Acta Neurol Scand. 1987;76(5):317-339.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Validity of the epidemics of multiple sclerosis in the Faroe Islands. Neuroepidemiology. 1988;7(4):190-227.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K, Arbuckle  JD,  et al.  Multiple sclerosis in the Faroe Islands, IV: the lack of a relationship between canine distemper and the epidemics of MS. Acta Neurol Scand. 1988;78(6):484-500.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K, Heltberg  A, Olsen  A.  Multiple sclerosis in the Faroe Islands, 5: the occurrence of the fourth epidemic as validation of transmission. Acta Neurol Scand. 1993;88(3):161-173.
PubMed   |  Link to Article
Jersild  C, Kurtzke  JF, Riisom  K, Heltberg  A, Arbuckle  J, Hyllested  K.  Multiple sclerosis in the Faroe Islands, VI: studies of HLA markers. Tissue Antigens. 1993;42(2):105-110.
PubMed   |  Link to Article
Kurtzke  JF.  A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5(8):580-583.
PubMed   |  Link to Article
Kurtzke  JF.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

John F. Kurtzke, MD

Tables

References

Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroes, 1: clinical and epidemiologic features. Trans Am Neurol Assoc. 1978;103:201-205.
PubMed
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, I: clinical and epidemiological features. Ann Neurol. 1979;5(1):6-21.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, II: clinical update, transmission, and the nature of MS. Neurology. 1986;36(3):307-328.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Multiple sclerosis in the Faroe Islands, III: an alternative assessment of the three epidemics. Acta Neurol Scand. 1987;76(5):317-339.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K.  Validity of the epidemics of multiple sclerosis in the Faroe Islands. Neuroepidemiology. 1988;7(4):190-227.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K, Arbuckle  JD,  et al.  Multiple sclerosis in the Faroe Islands, IV: the lack of a relationship between canine distemper and the epidemics of MS. Acta Neurol Scand. 1988;78(6):484-500.
PubMed   |  Link to Article
Kurtzke  JF, Hyllested  K, Heltberg  A, Olsen  A.  Multiple sclerosis in the Faroe Islands, 5: the occurrence of the fourth epidemic as validation of transmission. Acta Neurol Scand. 1993;88(3):161-173.
PubMed   |  Link to Article
Jersild  C, Kurtzke  JF, Riisom  K, Heltberg  A, Arbuckle  J, Hyllested  K.  Multiple sclerosis in the Faroe Islands, VI: studies of HLA markers. Tissue Antigens. 1993;42(2):105-110.
PubMed   |  Link to Article
Kurtzke  JF.  A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5(8):580-583.
PubMed   |  Link to Article
Kurtzke  JF.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

870 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient Have a Torn Meniscus or Ligament of the Knee?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Why Is the Diagnosis Important?